On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $32.15 which represents a slight increase of $1.81 or 5.97% from the prior close of $30.34. The stock opened at ...

Canaccord raised the firm’s price target on Hims & Hers to $38 from $28 and keeps a Buy rating on the shares. The stock rallied 70% in ...

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report)’s stock price gapped up prior to trading on Monday after Canaccord Genuity Group raised their price target on the stock from $28.00 to $38.00.

Shares of Hims & Hers were on fire Monday because the FDA's new leader seems to be a fan of the company's business model.

Hims & Hers' financials are robust, with strong and accelerating revenue growth, growing free cash flow, manageable SBC, and ...

Hims & Hers achieved a 44% YoY increase in Q3 2024, surpassing 2 million active users. Find out what positions HIMS as a key ...

Finding the right treatment for erectile dysfunction (ED) can feel overwhelming with so many options out there! Rugiet, ...

On Wednesday, Hims & Hers Health Inc (HIMS) stock saw a decline, ending the day at $30.34 which represents a decrease of $-0.34 or -1.11% from the prior close of $30.68. The stock opened at $31.49 and ...

Hims & Hers ( HIMS -0.72%) announced this week that it's getting into the nutrition business with bars and shakes. But are ...

Hims & Hers Health (HIMS) has soared after Hunterbrook Media says that the company could benefit from President-elect Donald ...

While Hims offers more options for sexual health and hair loss, Roman offers more options overall. Here’s our full breakdown of Hims vs. Roman for erectile dysfunction, hair loss, and more.

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...